Rx Countermeasures: HHS Launching "Pivotal Studies" To Engage Industry

HHS is hoping to redefine its relationship with biotech and pharmaceutical firms that are developing Rx countermeasures though a series of "pivotal studies" under which government works more closely with industry at the beginning stages of development

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet